# Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

> **NCT00711204** · PHASE4 · WITHDRAWN · sponsor: **Eisai Inc.**

## Conditions studied

- Severe Alzheimer's Disease

## Interventions

- **DRUG:** Donepezil Hydrochloride (Aricept)

## Key facts

- **NCT ID:** NCT00711204
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-01
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled in the study.
- **Last updated:** 2012-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00711204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00711204, "Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00711204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*